Inclusion Criteria:

          -  Age: at least 20 years of age

          -  Cytologically or histologically confirmed adenocarcinoma of locally advanced or
             metastatic NSCLC which is not amenable to curative surgery or radiotherapy

          -  Radiologically confirmed disease progression after at least one line of treatment with
             an EGFR-TKI

          -  At least one documented EGFR mutation which is known to be related with susceptibility
             to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q)

          -  World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at
             least 3 months

          -  Centrally confirmed T790M mutation positive tumor status from a tumor sample taken
             after confirmation of disease progression on the most recent anticancer treatment
             regimen

          -  At least one lesion (excluding the brain), not previously irradiated that can be
             accurately measured per RECIST version 1.1

          -  Adequate hematological and biological function

          -  Females of child-bearing potential must agree to use adequate contraception and for 3
             months after the last dose of study drug

          -  Male patients should be documented to be sterile or agree to use barrier contraception

          -  Recovery to ≤ Grade 1 or baseline of any toxicities, except for stable sensory
             neuropathy ≤ Grade 2 and alopecia

        Exclusion Criteria:

          -  Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs
             with a similar chemical structure of HM61713

          -  Previous treatment with anticancer therapies, EGFR-TKI, HM61713, or other drugs that
             target T790M-positive mutant EGFR with sparing of wild-type, investigational agent(s)
             within 28 days prior to the first administration of study drug, radiotherapy

          -  Any non-study related significant surgical procedures within the past 28 days prior to
             the first administration of study drug

          -  Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain
             metastases

          -  History of any other malignancy

          -  Clinically significant uncontrolled condition(s)

          -  Active or chronic pancreatitis

          -  Anyone with cardiac abnormalities or history

          -  Presence or history of ILD, drug-induced ILD, or presence of radiation pneumonitis

          -  Pregnant or breast feeding

          -  In the opinion of the investigator, the patient is an unsuitable candidate to receive
             HM61713